Climb Bio, Inc. (CLYM)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
HIGH DILUTION RISKDilution score: 51/100 (HIGH), 46.9 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 34.63% of float, squeeze risk: HIGH
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug
- Why Climb Bio, Up 1,300% Over 17 Months, Just Took A Tumble
- Climb Bio Phase I Data Backs 12-Week Dosing Plan for IgA Nephropathy Drug
- Climb Bio Shares Rise 17% After Phase 1 CLYM116 Trial Data
- Climb Bio to Present at Upcoming Investor Conferences
- Do Climb Bio’s (CLYM) Mixed Loss Trends Reveal a Shifting Path to Sustainable Scale?
- Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates
- Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Climb Bio, Inc..
Full CLYM Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.